Sexual Health & ED Medications

PT-141

An as-needed sexual-health option for selected low-desire, arousal, and responsiveness concerns.

Common goals: Clinically demonstrated improvement in sexual-desire scores and distress related to low desire for appropriately selected premenopausal women with acquired, generalized HSDD.
Best program fit: May fit a broader sexual-health offering that also reviews relationships, medications, hormones, pain, and mental-health factors.
Format: Clinician-confirmed formulation

Partner education guide

Where this may fit in an offering.

Clinically demonstrated improvement in sexual-desire scores and distress related to low desire for appropriately selected premenopausal women with acquired, generalized HSDD. Some individuals may notice greater desire, arousal, or responsiveness within hours of dosing. Provides a non-hormonal option that works through central melanocortin pathways.

Educational business-planning summary. Potential benefits vary, are not guaranteed, and require individual-specific clinical review.

01 / Common goals

What people may want to understand.

Primary goals

Potential benefits and goals

Clinically demonstrated improvement in sexual-desire scores and distress related to low desire for appropriately selected premenopausal women with acquired, generalized HSDD.
Some individuals may notice greater desire, arousal, or responsiveness within hours of dosing.
As-needed self-administration allows treatment to be timed around anticipated intimacy.

Program value

How it may support a program

Provides a non-hormonal option that works through central melanocortin pathways.
Can support a broader sexual-health plan addressing relationship, medication, hormonal, pain, and mental-health factors.

Approved benefits apply to the labeled HSDD population and dosing. Response varies, satisfying sexual events may not increase, and use outside the label requires separate clinical judgment.

02 / Program fit

Program and operational considerations.

01Administration: Catalog format: Clinician-confirmed formulation. The prescribing clinician and dispensing pharmacy confirm the exact preparation, concentration, handling, and administration technique.
02Typical frequency: As needed, at least 45 minutes before anticipated sexual activity; no more than one dose in 24 hours and no more than eight doses per month.
03Expected duration: Discontinue after eight weeks if symptoms have not improved. Duration of effect after each dose and the optimal administration window are not fully characterized.
04Practical advantages: Provides a non-hormonal option that works through central melanocortin pathways.

03 / Suitability considerations

Who may be considered.

Who may be considered

A carefully screened adult whose goals align with the potential benefits above and who understands that individual response varies.
An individual willing to complete clinician-directed baseline review, monitoring, and an outcome-based follow-up plan.

Qualification notes

Provides a non-hormonal option that works through central melanocortin pathways.
Strongest fit occurs when the exact formulation, route, source, contraindications, and measurable goals can be clearly documented.

04 / Safety & suitability

What must be screened before treatment.

Common or temporary

Nausea occurred in 40% of label-trial individuals, required anti-nausea treatment in 13%, and led 8% to stop early. Flushing, injection-site reactions, headache, and vomiting are also common.
Nausea often improves after the first dose but can remain treatment-limiting.

Serious or important

Each dose transiently increases blood pressure and reduces heart rate; label averages peaked around 6 mmHg systolic and 3 mmHg diastolic and usually returned to baseline within 12 hours.
Focal darkening of the face, gums, or breasts occurred in about 1% with intermittent labeled-frequency use; it is more likely with darker skin and frequent dosing and may not fully resolve.
Because gastric emptying is slowed, absorption of some oral medicines may be affected; interaction with oral naltrexone is specifically relevant.

Avoid or use only with specialist input

Uncontrolled hypertension or known cardiovascular disease, which are labeled contraindications.
Pregnancy or breastfeeding without explicit medical review, unexplained sexual symptoms, daily or high-frequency use, or a product that does not match the approved dose and delivery system.

Screening checklist

Confirm acquired generalized HSDD with distress; review blood pressure and cardiovascular risk, menopausal and pregnancy status, skin pigmentation concerns, nausea history, medicines including oral naltrexone and time-sensitive oral drugs, mood, trauma, relationship context, pain, and endocrine or gynecologic causes.
Reassess symptom improvement by eight weeks and track dose frequency and adverse effects.

When to refer

Chest pain, severe headache, markedly elevated blood pressure, fainting, persistent vomiting, significant pigmentation change, pregnancy, suicidality, pelvic pain, or suspected endocrine or gynecologic disease requires appropriate medical assessment.

Safety information is not exhaustive. Prescribing, screening, dosing, monitoring, and emergency guidance must come from an appropriately licensed clinician and the exact product information.

What the research says · reviewed August 2026

Research and source context.

Two large randomized trials support a narrow indication with modest benefit and common nausea.

01 / Human research

The clearest clinical signal

Two large phase 3 trials found small but statistically clear improvements in desire and distress in premenopausal women with acquired generalized low desire.

02 / Real-world reports

What people describe

About 14 detailed accounts were sampled. Many described increased desire or genital response within 30 minutes to several hours. Others had no effect. Nausea, vomiting, flushing, headache, darkened spots, and blood-pressure concern were frequent reasons not to repeat it.

Public personal accounts are unverified and cannot show how common an outcome is.

03 / Cautions

What deserves attention

Nausea, vomiting, flushing, headache, temporary blood-pressure rise, slower heart rate, and darkening of skin or gums. Cardiovascular disease and uncontrolled blood pressure need special care.

Does the research match this exact product?

The catalog does not state the studied dose or individual group.

Complete evidence briefClinical summary, safety notes, reported timing, regulatory context, and linked sources in one document.

Download the evidence briefPDF · larger type

Evidence and regulatory status can change. Confirm the current label, formulation, route, dose, pharmacy source, jurisdiction, and intended use before offering treatment.

Education before offering.

Treatment information is for education only. It is not medical advice. A licensed clinician will review your health and decide whether a treatment is appropriate for you. Eligibility and availability may vary.

Back to all treatments